Aurinia Pharmaceuticals is an Edmonton biopharmaceutical company focused on autoimmune diseases. Its commercial product is LUPKYNIS (voclosporin), and the company frames its mission around changing the trajectory of autoimmune disease, especially lupus nephritis. Aurinia’s science section also references pipeline work beyond LUPKYNIS, including aritinercept.